0001564590-21-024034.txt : 20210505 0001564590-21-024034.hdr.sgml : 20210505 20210505160612 ACCESSION NUMBER: 0001564590-21-024034 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 14 CONFORMED PERIOD OF REPORT: 20210429 ITEM INFORMATION: Results of Operations and Financial Condition ITEM INFORMATION: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers ITEM INFORMATION: Financial Statements and Exhibits FILED AS OF DATE: 20210505 DATE AS OF CHANGE: 20210505 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Turning Point Therapeutics, Inc. CENTRAL INDEX KEY: 0001595893 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 463826166 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-38871 FILM NUMBER: 21893221 BUSINESS ADDRESS: STREET 1: 10628 SCIENCE CENTER DRIVE, SUITE 200 CITY: SAN DIEGO STATE: CA ZIP: 92121 BUSINESS PHONE: 858-926-5251 MAIL ADDRESS: STREET 1: 10628 SCIENCE CENTER DRIVE, SUITE 200 CITY: SAN DIEGO STATE: CA ZIP: 92121 FORMER COMPANY: FORMER CONFORMED NAME: TP Therapeutics, Inc. DATE OF NAME CHANGE: 20181018 FORMER COMPANY: FORMER CONFORMED NAME: TP Therapeutics, INC DATE OF NAME CHANGE: 20140106 8-K 1 tptx-8k_20210429.htm 8-K tptx-8k_20210429.htm
false 0001595893 0001595893 2021-04-29 2021-04-29

 

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

 

FORM 8-K

 

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): April 29, 2021

 

TURNING POINT THERAPEUTICS, INC.

(Exact name of Registrant as Specified in Its Charter)

 

 

Delaware

001-38871

46-3826166

(State or Other Jurisdiction

of Incorporation)

(Commission File Number)

(IRS Employer

Identification No.)

 

 

 

10628 Science Center Drive, Suite 200, San Diego, CA

 

92121

(Address of Principal Executive Offices)

 

(Zip Code)

Registrant’s Telephone Number, Including Area Code: (858) 926-5251

N/A

(Former Name or Former Address, if Changed Since Last Report)

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instructions A.2. below):

Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class

Trading Symbol(s)

Name of each exchange on which registered

Common Stock, $0.0001 par value per share

TPTX

The Nasdaq Stock Market LLC

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 or Rule 12b-2 of the Securities Exchange Act of 1934.

Emerging growth company  

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.  

 

 

 


 

Item 2.02Results of Operations and Financial Condition.

On May 5, 2021, Turning Point Therapeutics, Inc. (the “Company”) issued a press release announcing the Company’s financial results for the first quarter ended March 31, 2021 and providing a corporate update. A copy of this press release is furnished herewith as Exhibit 99.1.

The information contained in this Current Report on Form 8-K under this Item 2.02, and Exhibit 99.1 hereto are being furnished and shall not be deemed to be “filed” for the purposes of Section 18 of the Securities and Exchange Act of 1934, as amended, or otherwise subject to the liabilities of that section and will not be incorporated by reference into any registration statement filed by the Company, under the Securities Act of 1933, as amended, unless specifically identified as being incorporated therein by reference.

 

Item 5.02

Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.

 

On April 29, 2021, Brian Baker notified the Company of his intention to resign from the Company and from his positions as principal financial officer and principal accounting officer, effective May 14, 2021, to pursue another opportunity.  Effective as of May 14, 2021, Athena Countouriotis, the Company’s President and Chief Executive Officer, will act as the Company’s interim principal financial officer, and Kyri Van Hoose, the Company’s Vice President, Accounting, will act as the Company’s interim principal accounting officer, for the purposes of the Securities Exchange Act of 1934, as amended.

 

Ms. Van Hoose joined the Company as Vice President, Accounting on May 5, 2021. Ms. Van Hoose previously served as chief financial officer of TEGA Therapeutics, Inc., a private biotechnology company, from September 2020 until May 2021. Prior to TEGA, Ms. Van Hoose served as Vice President, Finance for Curzion Pharmaceuticals, Inc., a private biopharmaceutical company, from November 2019 until its acquisition by Horizon Therapeutics plc in April 2020, and as Vice President, Finance of Avelas Biosciences, Inc., a clinical stage oncology company, from December 2017 to July 2019. From 2005 to 2016, Ms. Van Hoose held positions of increasing responsibilities at ACADIA Pharmaceuticals, Inc., a publicly traded biopharmaceutical company, most recently as Senior Director of Finance and Corporate Controller. Ms. Van Hoose began her career at Deloitte and is a licensed Certified Public Accountant (California active). Ms. Van Hoose earned her BS in Accounting at the University of Southern California and MBA in Finance at University of California, Irvine.  

 

There are no arrangements or understandings between Ms. Van Hoose and any other persons in connection with Ms. Van Hoose’s appointment as interim principal accounting officer. There are also no family relationships between Ms. Van Hoose and any director or executive officer of the Company and Ms. Van Hoose has no direct or indirect interest in any transaction or proposed transaction required to be disclosed pursuant to Item 404(a) of Regulation S-K.

Item 9.01 Financial Statements and Exhibits.

(d) Exhibits.

 

Exhibit

Number

 

Description

 

 

99.1

 

Press release issued by Turning Point Therapeutics, Inc. on May 5, 2021

 

 

 

 

104

Cover Page Interactive Data File (embedded within the Inline XBRL document).

 

 


 


 

 

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

 

 

 

TURNING POINT THERAPEUTICS, INC.

 

 

 

 

Date: May 5, 2021

 

By:

/s/ Annette North

 

 

 

Annette North

 

 

 

Executive Vice President and General Counsel

 

 

 

EX-99.1 2 tptx-ex991_8.htm EX-99.1 tptx-ex991_8.htm

Exhibit 99.1

 

FOR IMMEDIATE RELEASE

 

Contact:

Jim Mazzola

jim.mazzola@tptherapeutics.com

858-342-8272

 

 

TURNING POINT THERAPEUTICS REPORTS FIRST-QUARTER FINANCIAL RESULTS, PROVIDES OPERATIONAL UPDATES

 

 

FDA Type B Meeting Feedback Supports Discussion of Topline BICR Results for Repotrectinib in TKI-Naïve ROS1+ NSCLC Patients After 6 Months or Greater Follow-up; FDA Meeting Anticipated in 1Q 2022

 

 

Investigational New Drug Application Cleared for Combination of Repotrectinib and MEK-inhibitor Trametinib in KRAS-Driven Tumors; TRIDENT-2 Study on Track to Initiate Mid-Year

 

 

TPX-0022 SHIELD-1 Study Progressing Toward Recommended Phase 2 Dose

 

 

TPX-0131 Phase 1/2 FORGE-1 Study Initiated

 

 

Cash, Cash Equivalents, and Marketable Securities of $1.1 Billion Expected to Fund Current Operations into 2024

 

 

SAN DIEGO, May 5, 2021 – Turning Point Therapeutics, Inc. (NASDAQ: TPTX), a precision oncology company developing next-generation therapies that target genetic drivers of cancer, today reported financial results and operational updates for the first quarter ended March 31, 2021.

 

“Our team continues to execute well and has achieved multiple key milestones, including completing a Type B meeting with the FDA for our lead drug candidate, repotrectinib, as well as clearing our fourth IND and initiating our fourth clinical study in less than 2 years,” said Athena Countouriotis, M.D., president and CEO. “We are pleased with the feedback from the Type B meeting and look forward to the discussion with the FDA about the topline results from patients treated within cohort 1 of our TRIDENT-1 study, which we anticipate in the first quarter of next year.”

 

First quarter and recent highlights include:

 

1


 

REPOTRECTINIB, ROS1/TRK Inhibitor

Completion of a Type B meeting with the Food and Drug Administration (FDA) to discuss potential next steps for repotrectinib in patients treated within cohort 1 (EXP-1) of the registrational TRIDENT-1 study. The FDA guided that a meeting should be requested to discuss topline blinded independent central review (BICR) results when responders have been followed for at least six months past onset of response. Turning Point believes it may be in a position to discuss the topline results from patients treated within EXP-1 with the FDA during the first quarter of 2022.

 

Clearance of an investigational new drug (IND) application for the combination of repotrectinib and MEK-inhibitor trametinib in KRAS-driven tumors. The company anticipates the first cohort of its planned Phase 1b/2 TRIDENT-2 study will examine the safety, tolerability, pharmacokinetics, and any early signals of efficacy of repotrectinib in combination with trametinib in patients with KRAS mutant G12D advanced solid tumors. The study is planned for initiation in mid-2021.

 

Presentation of preclinical data at the American Association for Cancer Research (AACR) annual meeting demonstrating that repotrectinib in combination with trametinib was more effective than single-agent treatment of either repotrectinib or trametinib in patient-derived KRAS mutant G12D/V lung and G12D/V/R pancreatic cancer models.

 

In earlier preclinical studies, repotrectinib’s inhibition of SRC, FAK and JAK2 at therapeutically relevant concentrations in combination with trametinib demonstrated a synergistic effect over either single agent by reducing tumor cell growth and enhancing tumor cell death in a KRAS mutant G12D lung cancer model.

 

Progress in the ongoing Phase 1/2 CARE study in pediatric and young adult patients with advanced solid tumors harboring ALK, ROS1 or NTRK alterations. The company plans to report initial data from the study in the second half of 2021.

 

TPX-0022, MET/ SRC/CSF1R Inhibitor

Progress in the Phase 1 SHIELD-1 study of TPX-0022, Turning Point’s MET, SRC and CSF1R inhibitor, where the company continues to enroll patients and evaluate multiple doses and schedules to further characterize the pharmacokinetics, safety and efficacy profile before determining a recommended Phase 2 dose (RP2D), anticipated in the second quarter of 2021. Turning Point plans to proceed directly into multiple Phase 1 dose expansion cohorts after determining the RP2D and to prepare for an end of Phase 1 meeting in the second half of 2021.

 

Presentation of preclinical data at AACR demonstrating potential utility of TPX-0022 in combination with immune checkpoint inhibitors. In a syngeneic xenograft tumor model, TPX-0022 downregulated immunosuppressive cytokines, increased anti-tumor M1 macrophages, and enriched levels of CD8-positive cytotoxic T cells. TPX-0022 had single agent in vivo efficacy and enhanced the efficacy of an anti-PD-1 inhibitor. The company is evaluating a clinical combination study of TPX-0022 and an anti-PD-1 checkpoint inhibitor.

 

TPX-0046, RET Inhibitor

2


Reporting initial data from the Phase 1 dose finding portion of the Phase 1/2 SWORD-1 study, which showed preliminary clinical activity, including objective responses and a generally well-tolerated safety profile in patients with RET-positive non-small cell lung cancer (NSCLC) and medullary thyroid carcinoma.

 

Progress in the ongoing dose-finding portion of the study, where the company continues to evaluate multiple doses and schedules to further characterize the pharmacokinetics, safety, and efficacy profile before determining the RP2D. The company has revised the study protocol to include multiple Phase 1 dose expansion cohorts following determination of the RP2D.

 

TPX-0131, ALK Inhibitor

Clearance of the IND for TPX-0131, the company’s fourth drug candidate, which has a compact macrocyclic structure that has been shown in preclinical studies to potently inhibit wildtype ALK and numerous ALK mutations, and in in-vivo studies has shown brain tissue penetration after repeat oral dosing.

 

Initiation of the Phase 1/2 FORGE-1 study of TPX-0131 in patients with locally advanced or metastatic TKI-pretreated ALK-positive NSCLC. The study endpoints include safety and tolerability, determination of the maximum tolerated dose and/or the recommended Phase 2 dose, and objective response rate by RECIST 1.1.

 

Presentation of preclinical data at AACR demonstrating the potential for TPX-0131 to cross the blood-brain barrier in vivo, and potency against wild type ALK (IC50=0.4 nM) and a broad spectrum of acquired ALK resistance mutations, including the G1202R solvent front mutation (IC50=0.2 nM), L1196M gatekeeper mutation (IC50=0.5 nM), and multiple compound mutations (IC50< 1 nM) based on cell proliferation assays.

 

First Quarter Financial Results

 

 

Revenue: Revenue of $25.2 million recognized during the quarter included a $25 million upfront payment from Zai Lab (Shanghai) Co. Ltd., under the company’s license agreement for TPX-0022 in Greater China, and $0.2 million from clinical drug supply to Zai Lab under the company’s repotrectinib license agreement.

 

 

R&D Expenses: Research and development expenses were $41.3 million in the quarter, compared to $22.8 million in the first quarter of 2020. The $18.5 million increase was primarily driven by the year-over-year increase in investments to develop repotrectinib, TPX-0022, TPX-0046 and TPX-0131, discovery efforts and personnel expenses.

 

 

G&A Expenses: General and administrative expenses were $20 million compared to $39.9 million in the first quarter of 2020. Excluding a one-time non-cash stock-based compensation charge from the first quarter of 2020, non-GAAP G&A expenses increased by $11.5 million, primarily related to higher personnel expenses from an increase in head count and professional services.

 

 

Net Income/Loss: Net loss was $35.5 million compared to a net loss of $60.7 million for the first quarter of 2020, and excluding the one-time non-cash stock-

3


 

based compensation charge from the first quarter of 2020, non-GAAP net loss increased by $6.2 million.

 

 

Cash position: Cash, cash equivalents and marketable securities at March 31, 2021 totaled $1.1 billion, compared to $1.1 billion as of Dec. 31, 2020, driven primarily by $25.2 million in revenue, partially offset by cash used in operating activities. Net cash used in operating activities during the first quarter was $15.7 million. Turning Point projects its cash position funds current operations into 2024.

 

Upcoming Milestones

Key milestones anticipated in 2021 include:

 

Repotrectinib

 

Reach enrollment of 50 patients pooled from the Phase 1 and Phase 2 portions of the TRIDENT-1 study in the ROS1-positive TKI-naïve NSCLC patient cohort (EXP-1) in second quarter

 

 

Initiate the first cohort of a multi-arm Phase 1b/2 TRIDENT-2 combination study in patients with KRAS mutant G12D advanced solid tumors mid-year

 

 

Provide an enrollment and clinical data update from the Phase 2 TRIDENT-1 study in the second half

 

 

Report initial clinical data from the ongoing Phase 1/2 CARE study in pediatric and young adult patients in the second half

 

 

TPX-0022

 

Provide a clinical data update from the Phase 1 dose finding portion of the SHIELD-1 study in the second half

 

 

Initiate the Phase 2 portion of the SHIELD-1 study of TPX-0022, pending FDA feedback, in the second half

 

 

Initiate the Phase 1b/2 SHIELD-2 study of TPX-0022 in combination with an epidermal growth factor receptor (EGFR) targeted therapy in the second half

 

Preclinical/Research

 

Outline research strategy in the second half, including anticipated timeline to development candidates.

 

Webcast and Conference Call

Turning Point will webcast its Quarterly Update Conference Call today, May 5 at 5:00 p.m. ET/2:00 p.m. PT. Dr. Countouriotis will host the call, which will be accessible through the "Investors" section of tptherapeutics.com or by dialing (877) 388-2118 (in the United States) or (470) 495-9489 (outside the U.S.) using conference ID 7397513. A replay will be available through the "Investors" section of www.tptherapeutics.com.

 

About Turning Point Therapeutics Inc.

4


Turning Point Therapeutics is a clinical-stage precision oncology company with a pipeline of internally discovered investigational drugs designed to address key limitations of existing cancer therapies. The company’s lead drug candidate, repotrectinib, is a next-generation kinase inhibitor targeting the ROS1 and TRK oncogenic drivers of non-small cell lung cancer and advanced solid tumors. Repotrectinib, which is being studied in a registrational Phase 2 study in adults and a Phase 1/2 study in pediatric patients, has shown antitumor activity and durable responses among kinase inhibitor treatment-naïve and pre-treated patients. The company’s pipeline of drug candidates also includes TPX-0022, targeting MET, CSF1R and SRC, which is being studied in a Phase 1 trial of patients with advanced or metastatic solid tumors harboring genetic alterations in MET; TPX-0046, targeting RET, which is being studied in a Phase 1/2 trial of patients with advanced or metastatic solid tumors harboring genetic alterations in RET; and TPX-0131, a next-generation ALK inhibitor, which is being studied in a Phase 1/2 trial of previously treated patients with ALK-positive advanced or metastatic non-small cell lung cancer. Turning Point’s next-generation kinase inhibitors are designed to bind to their targets with greater precision and affinity than existing therapies, with a novel, compact structure that has demonstrated an ability to potentially overcome treatment resistance common with other kinase inhibitors. The company is driven to develop therapies that mark a turning point for patients in their cancer treatment. For more information, visit www.tptherapeutics.com.

 

###

 

 

Non-GAAP Financial Measures

In addition to the financial results that are provided in accordance with accounting principles generally accepted in the United States (GAAP), this press release also contains non-GAAP financial measures. When preparing our supplemental non-GAAP financial results, the Company excluded certain GAAP items that management does not consider to be normal. In particular, the non-GAAP measures exclude non-cash stock-based compensation expense relating to a one-time charge of $31.4 million associated with previously disclosed modifications to the vesting of existing stock options, pursuant to the transition agreement with the company’s scientific founder. These non-GAAP measures are provided as a complement to results provided in accordance with GAAP as management believes these non-GAAP financial measures are important in comparing current results with prior-period results. A reconciliation of the GAAP financial results to non-GAAP financial results is included in the attached financial information.

 

Forward Looking Statements

Statements contained in this press release regarding matters that are not historical facts are “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. Such forward-looking statements include statements regarding, among other things, the efficacy, safety and therapeutic potential of Turning Point Therapeutics’ drug candidates, repotrectinib, TPX-0022, TPX-0046 and TPX-0131, the results, conduct, progress and timing of Turning Point Therapeutics’ research and development programs and clinical trials, plans regarding future data presentations, clinical trials, regulatory meetings and regulatory submissions, the regulatory approval path for repotrectinib, and the strength of Turning Point Therapeutics’ balance sheet and the adequacy of cash on hand. Because such statements are subject to risks and uncertainties, actual results may differ materially from those expressed or implied by such forward-looking statements. Words such as “plans”, “will”, “believes,” “anticipates,”

5


“expects,” “intends,” “goal,” “potential” and similar expressions are intended to identify forward-looking statements. These forward-looking statements are based upon Turning Point Therapeutics’ current expectations and involve assumptions that may never materialize or may prove to be incorrect. Actual results could differ materially from those anticipated in such forward-looking statements as a result of various risks and uncertainties, which include, without limitation, risks and uncertainties associated with Turning Point Therapeutics’ business in general, risks and uncertainties related to the impact of the COVID-19 pandemic to Turning Point’s business and the other risks described in Turning Point Therapeutics’ filings with the SEC. All forward-looking statements contained in this press release speak only as of the date on which they were made. Turning Point Therapeutics undertakes no obligation to update such statements to reflect events that occur or circumstances that exist after the date on which they were made.


6


 

TURNING POINT THERAPEUTICS, INC.

Balance Sheet Data

 

(In thousands)

(unaudited)

 

 

 

 

March 31,

 

 

December 31,

 

 

 

 

2021

 

 

2020

 

 

Balance Sheet Data:

 

 

 

 

 

 

 

 

 

Cash, cash equivalents, and marketable securities

 

$

1,114,777

 

 

$

1,122,508

 

 

Working capital

 

 

1,097,541

 

 

 

1,106,287

 

 

Total assets

 

 

1,127,584

 

 

 

1,136,713

 

 

Accumulated deficit

 

 

(315,680

)

 

 

(280,176

)

 

Total stockholders' equity

 

$

1,101,165

 

 

$

1,109,898

 

 

 


7


 

TURNING POINT THERAPEUTICS, INC.

STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS

(In thousands, except share and per share amounts)

(unaudited)

 

 

 

 

Three Months Ended March 31,

 

 

 

 

2021

 

 

2020

 

 

Revenue

 

$

25,205

 

 

$

-

 

 

Operating expenses:

 

 

 

 

 

 

 

 

 

Research and development

 

 

41,263

 

 

 

22,769

 

 

General and administrative

 

 

19,991

 

 

 

39,857

 

 

Total operating expenses

 

 

61,254

 

 

 

62,626

 

 

Loss from operations

 

 

(36,049

)

 

 

(62,626

)

 

Other income, net

 

 

545

 

 

 

1,908

 

 

Net loss

 

 

(35,504

)

 

 

(60,718

)

 

Unrealized loss on marketable securities

 

 

(186

)

 

 

(316

)

 

Comprehensive loss

 

$

(35,690

)

 

$

(61,034

)

 

Net loss per share, basic and diluted

 

$

(0.73

)

 

$

(1.69

)

 

Weighted-average common shares outstanding, basic and diluted

 

 

48,920,403

 

 

 

35,919,358

 

 

 


8


 

TURNING POINT THERAPEUTICS, INC.

Reconciliation of GAAP to Non-GAAP Financial Results

 

(In thousands)

(unaudited)

 

 

 

 

Three Months Ended March 31,

 

 

 

 

2021

 

 

2020

 

 

GAAP Net Loss

 

$

(35,504

)

 

$

(60,718

)

 

Adjustments:

 

 

 

 

 

 

 

 

 

Share-based compensation expense (1)

 

 

 

 

 

31,405

 

 

Non-GAAP Net Loss

 

$

(35,504

)

 

$

(29,313

)

 

 

 

 

Three Months Ended March 31,

 

 

 

 

2021

 

 

2020

 

 

GAAP General & Administrative

 

$

(19,991

)

 

$

(39,857

)

 

Adjustments:

 

 

 

 

 

 

 

 

 

Share-based compensation expense (1)

 

 

 

 

 

31,405

 

 

Non-GAAP General & Administrative

 

$

(19,991

)

 

$

(8,452

)

 

 

(1)

During the first quarter of 2020, the Company recognized in non-cash stock-based compensation expense a one-time charge of $31.4 million associated with previously disclosed modifications to the vesting of existing stock options, pursuant to the transition agreement with the company’s scientific founder.

 

 

 

9

GRAPHIC 3 gmz5dn4dz2ut000001.jpg GRAPHIC begin 644 gmz5dn4dz2ut000001.jpg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tptx-20210429.xsd XBRL TAXONOMY EXTENSION SCHEMA 00000 - Document - Template Link link:presentationLink link:calculationLink link:definitionLink 100000 - Document - Document and Entity Information link:calculationLink link:presentationLink link:definitionLink EX-101.LAB 5 tptx-20210429_lab.xml XBRL TAXONOMY EXTENSION LABEL LINKBASE Entity Central Index Key Cover [Abstract] Document Type Document Type Amendment Flag Amendment Flag Document Period End Date Document Period End Date Entity Registrant Name Entity Registrant Name Entity Central Index Key Entity Emerging Growth Company Entity Emerging Growth Company Entity File Number Entity File Number Entity Incorporation, State or Country Code Entity Incorporation State Country Code Entity Tax Identification Number Entity Tax Identification Number Entity Address, Address Line One Entity Address Address Line1 Entity Address, Address Line Two Entity Address Address Line2 Entity Address, City or Town Entity Address City Or Town Entity Address, State or Province Entity Address State Or Province Entity Address, Postal Zip Code Entity Address Postal Zip Code City Area Code City Area Code Local Phone Number Local Phone Number Written Communications Written Communications Soliciting Material Soliciting Material Pre-commencement Tender Offer Pre Commencement Tender Offer Pre-commencement Issuer Tender Offer Pre Commencement Issuer Tender Offer Title of 12(b) Security Security12b Title Trading Symbol Trading Symbol Security Exchange Name Security Exchange Name EX-101.PRE 6 tptx-20210429_pre.xml XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE XML 7 tptx-8k_20210429_htm.xml IDEA: XBRL DOCUMENT 0001595893 2021-04-29 2021-04-29 false 0001595893 8-K 2021-04-29 TURNING POINT THERAPEUTICS, INC. DE 001-38871 46-3826166 10628 Science Center Drive Suite 200 San Diego CA 92121 (858) 926-5251 false false false false Common Stock, $0.0001 par value per share TPTX NASDAQ false XML 8 R1.htm IDEA: XBRL DOCUMENT v3.21.1
Document and Entity Information
Apr. 29, 2021
Cover [Abstract]  
Document Type 8-K
Amendment Flag false
Document Period End Date Apr. 29, 2021
Entity Registrant Name TURNING POINT THERAPEUTICS, INC.
Entity Central Index Key 0001595893
Entity Emerging Growth Company false
Entity File Number 001-38871
Entity Incorporation, State or Country Code DE
Entity Tax Identification Number 46-3826166
Entity Address, Address Line One 10628 Science Center Drive
Entity Address, Address Line Two Suite 200
Entity Address, City or Town San Diego
Entity Address, State or Province CA
Entity Address, Postal Zip Code 92121
City Area Code (858)
Local Phone Number 926-5251
Written Communications false
Soliciting Material false
Pre-commencement Tender Offer false
Pre-commencement Issuer Tender Offer false
Title of 12(b) Security Common Stock, $0.0001 par value per share
Trading Symbol TPTX
Security Exchange Name NASDAQ
EXCEL 9 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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end XML 10 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 11 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 12 FilingSummary.xml IDEA: XBRL DOCUMENT 3.21.1 html 1 96 1 false 0 0 false 0 false false R1.htm 100000 - Document - Document and Entity Information Sheet http://www.tptherapeutics.com/20210429/taxonomy/role/DocumentDocumentAndEntityInformation Document and Entity Information Cover 1 false false All Reports Book All Reports tptx-8k_20210429.htm tptx-20210429.xsd tptx-20210429_lab.xml tptx-20210429_pre.xml tptx-ex991_8.htm http://xbrl.sec.gov/dei/2020-01-31 true false JSON 14 MetaLinks.json IDEA: XBRL DOCUMENT { "instance": { "tptx-8k_20210429.htm": { "axisCustom": 0, "axisStandard": 0, "contextCount": 1, "dts": { "definitionLink": { "remote": [ "http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-eedm-def-2020-01-31.xml", "http://xbrl.fasb.org/srt/2020/elts/srt-eedm1-def-2020-01-31.xml" ] }, "inline": { "local": [ "tptx-8k_20210429.htm" ] }, "labelLink": { "local": [ "tptx-20210429_lab.xml" ], "remote": [ "https://xbrl.sec.gov/dei/2020/dei-doc-2020-01-31.xml" ] }, "presentationLink": { "local": [ "tptx-20210429_pre.xml" ] }, "referenceLink": { "remote": [ "https://xbrl.sec.gov/dei/2020/dei-ref-2020-01-31.xml" ] }, "schema": { "local": [ "tptx-20210429.xsd" ], "remote": [ "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "https://xbrl.sec.gov/country/2020/country-2020-01-31.xsd", "http://www.xbrl.org/dtr/type/nonNumeric-2009-12-16.xsd", "https://xbrl.sec.gov/currency/2020/currency-2020-01-31.xsd", "https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd", "http://www.xbrl.org/dtr/type/numeric-2009-12-16.xsd", "https://xbrl.sec.gov/exch/2020/exch-2020-01-31.xsd", "http://www.xbrl.org/lrr/arcrole/factExplanatory-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd", "https://xbrl.sec.gov/naics/2017/naics-2017-01-31.xsd", "https://xbrl.sec.gov/sic/2020/sic-2020-01-31.xsd", "http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd", "http://www.xbrl.org/2006/ref-2006-02-27.xsd", "http://xbrl.fasb.org/srt/2020/elts/srt-types-2020-01-31.xsd", "http://xbrl.fasb.org/srt/2020/elts/srt-roles-2020-01-31.xsd", "https://xbrl.sec.gov/stpr/2018/stpr-2018-01-31.xsd", "http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd", "http://xbrl.fasb.org/us-gaap/2020/elts/us-roles-2020-01-31.xsd", "http://xbrl.fasb.org/us-gaap/2020/elts/us-types-2020-01-31.xsd", "http://www.xbrl.org/lrr/role/deprecated-2009-12-16.xsd" ] } }, "elementCount": 24, "entityCount": 1, "hidden": { "http://xbrl.sec.gov/dei/2020-01-31": 2, "total": 2 }, "keyCustom": 0, "keyStandard": 96, "memberCustom": 0, "memberStandard": 0, "nsprefix": "tptx", "nsuri": "http://www.tptherapeutics.com/20210429", "report": { "R1": { "firstAnchor": { "ancestors": [ "p", "body", "html" ], "baseRef": "tptx-8k_20210429.htm", "contextRef": "C_0001595893_20210429_20210429", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "document", "isDefault": "true", "longName": "100000 - Document - Document and Entity Information", "role": "http://www.tptherapeutics.com/20210429/taxonomy/role/DocumentDocumentAndEntityInformation", "shortName": "Document and Entity Information", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "p", "body", "html" ], "baseRef": "tptx-8k_20210429.htm", "contextRef": "C_0001595893_20210429_20210429", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } } }, "segmentCount": 0, "tag": { "dei_AmendmentFlag": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.", "label": "Amendment Flag", "terseLabel": "Amendment Flag" } } }, "localname": "AmendmentFlag", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.tptherapeutics.com/20210429/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_CityAreaCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Area code of city", "label": "City Area Code", "terseLabel": "City Area Code" } } }, "localname": "CityAreaCode", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.tptherapeutics.com/20210429/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_CoverAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Cover page.", "label": "Cover [Abstract]" } } }, "localname": "CoverAbstract", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "xbrltype": "stringItemType" }, "dei_DocumentPeriodEndDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The end date of the period reflected on the cover page if a periodic report. For all other reports and registration statements containing historical data, it is the date up through which that historical data is presented. If there is no historical data in the report, use the filing date. The format of the date is YYYY-MM-DD.", "label": "Document Period End Date", "terseLabel": "Document Period End Date" } } }, "localname": "DocumentPeriodEndDate", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.tptherapeutics.com/20210429/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "dateItemType" }, "dei_DocumentType": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.", "label": "Document Type", "terseLabel": "Document Type" } } }, "localname": "DocumentType", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.tptherapeutics.com/20210429/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "submissionTypeItemType" }, "dei_EntityAddressAddressLine1": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 1 such as Attn, Building Name, Street Name", "label": "Entity Address Address Line1", "terseLabel": "Entity Address, Address Line One" } } }, "localname": "EntityAddressAddressLine1", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.tptherapeutics.com/20210429/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressAddressLine2": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 2 such as Street or Suite number", "label": "Entity Address Address Line2", "terseLabel": "Entity Address, Address Line Two" } } }, "localname": "EntityAddressAddressLine2", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.tptherapeutics.com/20210429/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressCityOrTown": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the City or Town", "label": "Entity Address City Or Town", "terseLabel": "Entity Address, City or Town" } } }, "localname": "EntityAddressCityOrTown", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.tptherapeutics.com/20210429/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressPostalZipCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Code for the postal or zip code", "label": "Entity Address Postal Zip Code", "terseLabel": "Entity Address, Postal Zip Code" } } }, "localname": "EntityAddressPostalZipCode", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.tptherapeutics.com/20210429/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressStateOrProvince": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the state or province.", "label": "Entity Address State Or Province", "terseLabel": "Entity Address, State or Province" } } }, "localname": "EntityAddressStateOrProvince", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.tptherapeutics.com/20210429/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "stateOrProvinceItemType" }, "dei_EntityCentralIndexKey": { "auth_ref": [ "r5" ], "lang": { "en-us": { "role": { "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.", "label": "Entity Central Index Key", "terseLabel": "Entity Central Index Key" } } }, "localname": "EntityCentralIndexKey", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.tptherapeutics.com/20210429/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "centralIndexKeyItemType" }, "dei_EntityEmergingGrowthCompany": { "auth_ref": [ "r5" ], "lang": { "en-us": { "role": { "documentation": "Indicate if registrant meets the emerging growth company criteria.", "label": "Entity Emerging Growth Company", "terseLabel": "Entity Emerging Growth Company" } } }, "localname": "EntityEmergingGrowthCompany", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.tptherapeutics.com/20210429/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_EntityFileNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.", "label": "Entity File Number", "terseLabel": "Entity File Number" } } }, "localname": "EntityFileNumber", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.tptherapeutics.com/20210429/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "fileNumberItemType" }, "dei_EntityIncorporationStateCountryCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Two-character EDGAR code representing the state or country of incorporation.", "label": "Entity Incorporation State Country Code", "terseLabel": "Entity Incorporation, State or Country Code" } } }, "localname": "EntityIncorporationStateCountryCode", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.tptherapeutics.com/20210429/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "edgarStateCountryItemType" }, "dei_EntityRegistrantName": { "auth_ref": [ "r5" ], "lang": { "en-us": { "role": { "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.", "label": "Entity Registrant Name", "terseLabel": "Entity Registrant Name" } } }, "localname": "EntityRegistrantName", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.tptherapeutics.com/20210429/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityTaxIdentificationNumber": { "auth_ref": [ "r5" ], "lang": { "en-us": { "role": { "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.", "label": "Entity Tax Identification Number", "terseLabel": "Entity Tax Identification Number" } } }, "localname": "EntityTaxIdentificationNumber", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.tptherapeutics.com/20210429/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "employerIdItemType" }, "dei_LocalPhoneNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Local phone number for entity.", "label": "Local Phone Number", "terseLabel": "Local Phone Number" } } }, "localname": "LocalPhoneNumber", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.tptherapeutics.com/20210429/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_PreCommencementIssuerTenderOffer": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.", "label": "Pre Commencement Issuer Tender Offer", "terseLabel": "Pre-commencement Issuer Tender Offer" } } }, "localname": "PreCommencementIssuerTenderOffer", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.tptherapeutics.com/20210429/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_PreCommencementTenderOffer": { "auth_ref": [ "r3" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.", "label": "Pre Commencement Tender Offer", "terseLabel": "Pre-commencement Tender Offer" } } }, "localname": "PreCommencementTenderOffer", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.tptherapeutics.com/20210429/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_Security12bTitle": { "auth_ref": [ "r0" ], "lang": { "en-us": { "role": { "documentation": "Title of a 12(b) registered security.", "label": "Security12b Title", "terseLabel": "Title of 12(b) Security" } } }, "localname": "Security12bTitle", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.tptherapeutics.com/20210429/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "securityTitleItemType" }, "dei_SecurityExchangeName": { "auth_ref": [ "r1" ], "lang": { "en-us": { "role": { "documentation": "Name of the Exchange on which a security is registered.", "label": "Security Exchange Name", "terseLabel": "Security Exchange Name" } } }, "localname": "SecurityExchangeName", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.tptherapeutics.com/20210429/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "edgarExchangeCodeItemType" }, "dei_SolicitingMaterial": { "auth_ref": [ "r4" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.", "label": "Soliciting Material", "terseLabel": "Soliciting Material" } } }, "localname": "SolicitingMaterial", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.tptherapeutics.com/20210429/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_TradingSymbol": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Trading symbol of an instrument as listed on an exchange.", "label": "Trading Symbol", "terseLabel": "Trading Symbol" } } }, "localname": "TradingSymbol", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.tptherapeutics.com/20210429/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "tradingSymbolItemType" }, "dei_WrittenCommunications": { "auth_ref": [ "r6" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.", "label": "Written Communications", "terseLabel": "Written Communications" } } }, "localname": "WrittenCommunications", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.tptherapeutics.com/20210429/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" } }, "unitCount": 0 } }, "std_ref": { "r0": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b" }, "r1": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "d1-1" }, "r2": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "13e", "Subsection": "4c" }, "r3": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "14d", "Subsection": "2b" }, "r4": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "14a", "Subsection": "12" }, "r5": { "Name": "Regulation 12B", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b-2" }, "r6": { "Name": "Securities Act", "Number": "230", "Publisher": "SEC", "Section": "425" } }, "version": "2.1" } ZIP 15 0001564590-21-024034-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001564590-21-024034-xbrl.zip M4$L#!!0 ( ,6 I5*K YEPL@0 -46 1 ='!T>"TR,#(Q,#0R.2YX M,9W$0>0 SE"6$+:Z]0OA0 M($*\CS>__G+UF^^#\=W] [A%DCSC,1&(9J+@^-WCE_?@VQ_3"7A$2YQ",,Y0 MD6(F@0^64N:C,'QY>0F2.6$BHX54ID2 LC0$OF\5?^(8:@(80XF!>4:@%_5B M/^JKGZ?H;-2/1OTXN+PX'_0&P]^C:!1%#05_EWL C6<$^D$4Q,%%W&\P?H7H M!UQ@<#]N, X'L]Y@WH]F@QXZ[Z/SRVB&S]5OB!4$A)N&/F7YFI/%4H)WZ+V! MJ/;+&*84K\$=89 A BEXM#O] .X9"L MI6"JQ0288H'Y,TZ"2NM*)"-1>DY% M@XD14_J*]-IK.&\UXS3(^"),) _E.L>A8O(5%^8$>95<@DDM9 0$1L$B>PX5 M(51((S^*_;/8LI]@8UN_R@>]+&JI.10S(V$I#BM"YMR-2E.40'RY(\#E(3,U MR66'H -F"'*P:Y9$;DMH$[THZH E,P)3E1WI%BWMBV&!EE"OL#R :98 MY!#ATTU7/A2)RX/*WW'X[:AH F+9!TCSC$I3=8Y(ATT./Q$Q_^38] M?+WDQSWEKD I\P!SPCZ46^$K8=C\Z01CDWR=8=@RU_;[ARR[^\)I-L6Q4K,? M_B9GCV(X5JY=X33KK/YJ#VL=EKSMV\03D/(4<\HUB=K$A^7N44,B@S M4T:M'*/9MW3Y>*/L3GV_!J-1RO!"76633L":"MX B'P-B.[M;G-]*5_]S4WF MI*S9O_YT!&)O@/JE;>KNWAY/#H;1LG==##&5PMQC_QO'P;OFFV'0(18MD91" M/P>/N=NWQ;,_$'1-$SN/F#=_,YF&(&'DWZ:WI_ZB!0=MUM%>VFL1J:!9?@.6'$;"32#_";_Z"QIH"V=17N2NPJ M*P1._F0WYCWG6"@EQD<-Z8KEF"2"%!6T@^ &V6&Y:M7&9"=4UD]3/ =F)AU5 MMX#CDVN8\RS'7!*5,(W!URA8A_WV[*A7:;G]R[_MK@:KWY MNBS;%J&$JXQEZ;I$:JO%_KUER6>F\*WO52?@J<'FF=*?*O;O)[$?J]+84:;U M*V0)*-6!AKYVA=NY_+I7?/?"O0IW^VZUTNS/Y5)Y>MS\"U!+ P04 " #% M@*52W1(_(BX' "%3 %0 '1P='@M,C R,3 T,CE?;&%B+GAM;,U<:V_; M-A3]/F#_@7._M%AER4K2-$:3(G.2P5B:!+&[%1N&0I9IAQA-&J2GSZK2=%H#$IV-$IN>M!;<\ M[B/4 CSPR-C#E,#SU@KRUN>+GW_Z](ME@:N;_AVX] /T#*\0]S'E"P;?#KZ\ M ]]^>[P%MXC\-_(X!%?47\P@"8 %GH)@WK7MEY>7]GB""*=X$0AVWO;IS :6 ME4#W&/3D/\"5%T 0/KK ==R.Y9R(GZ%SU#UQNB>=]L/Y_WA2"_E6JX=GIR#V=G#BC4]<_/O&//SHC M>"Q^>U"$X,,T48_.5PQ-GP+PUG\7ABC&2PC$&*[ #2(>\9&'P2 9Z7O0)WX; M7&(,'F4W#AXAA^P9CMLQ*A:Z=7$BGL@1X>'3\U9*O>6(X39E4]MUG",[:=V* MFR^WVK\)5 D7^)* HRX/3]Y2 M/\Q1B;A ;@OYS$J:6?*4U7&MHTY[R<42%):CM+1&_@A-O@0-EF&&( M6P!BEG)LB ,NST@T;LE3EM.)K[QO%+CY@8>AR-D^;BD1"R:%*/QH"DHAPV4 MR1C&5_TU-O6WQL63@7'HMZ?TV1Y#%(U)'&R.1)SZ?DT"%*QZ8@G"/-P7),L_ MX"K+CN5D1EER,AS2>:N@LYT-4[:7,ZHXDJLG2*RO@[)@W_%HPQX,%6O@RQ$79'Y0UA4;G>JY(0.BQP61[![HP"W270J8ICNN+?=B=8C;P"IM$ M?95X/8-LBLCT=T9?@J<>G+],Z"N$&X3AW6(V@JR:^]/]]M'X%:BXXH)J!]0^DA="-^;S#.M[$/("RD#, M#22Y*050+H^THJB&YPSGIRO.5KE4Z2NGH;?LC\7Z"TU0]%IZG:D@%V2?=.2 M-E8\@@]D"0V;,G:EBI96S]BTX'TSHJ\P+L=C,0(>_[E%!':J%8428!_E%8"- M%4-,\CXYD&^E@N">&#-]%*6'EE+-R%1@518R2>@9WRYK?;<+\FE*QV_SN#S1_3QS>LR%](;6LG^ZN0>U7N.9M+[GDMD&R&69Y M15)4AM]4R\ $J,T>2G^_2WKM7@_W'O?L@=%G1/R*V^@\# VB;V V;_WUECFA M-,S_>8E2%8%2/%.3HBZ'*!WW9=*AO28>* \\_#>:5[^QI$;0('T&L?EJB.B MX#/JUE%A@E25H)#-S&2HJZ!T&K2\%U$.D$&OBNNS?6J^$S&%H=_9X;PJX0TQ MLE)EFJ>$*8KB:F+JL*/\B ]^>**DXFM4V_WJB;B)H]^:(0,(*8RYX9BK.BU2 MQ22%<75Q==CU+X:" )(>G3G M35T?.3J:G*.\6JF4'BT+'N@OQ#IKU7%'0Q3@TO=!MOO5G(,WC=R A/+SK+_TG,5Q8Y3-/ZK[[%7H:JX'M8\P" M$AI#/O-4F 6Z2R'3%,>5Q$Z?N!5'\MNMXE,H^L:GB_\!4$L#!!0 ( ,6 MI5*72*PG"P4 +DM 5 ='!T>"TR,#(Q,#0R.5]P&ULY5I;C]HX M%'Y?:?^#-WUIM9L;EU+0T(IE9E9HF1D$[&ZU+Y5Q#%AU[,@.MW^_QX$0&$(' MVJ9:*0AQ2<[E\Y>3CKT<,;]/'W81_U MF?@\P9JB6TD6(14QLM$\CJ.6ZZY6*R>8,J$E7\3@73M$ABZR[=1T5U%L3J!; M'%.4O%JHXE5\VZO#>^Q56W6O5?>==V]KC4JC^:OGM3SOP,#?VV&A@U<+U1W/ M\9VW?OU <(#)9SRCJ'=[(-AL3"J-:=V;-"JD5B>U=]Z$UN 34X! Z*&CKHPV MBLWF,7I-WB008;Q"4,[I!MTS@05AF*-1.M+?4$\0!W4X1T.CIM&0:JJ6-'!V M5CGPUN(I>7"-A$[^MJT#]M83Q1VI9F[%\ZIN*FWMQ-'_HC,:8AMN%00!<0XT*REDX-]29)K= $N=%;"_+-3,=LX4F1I7@'@NG#/=J 7Z\K@XGO]6*< 4-LBT0D"J%-Z(*$SX?^R MZ!J(7[)0-. 1%%;ZI 9*+MFVH[H>\HF-HD&;:_JDQG(EO@KOH7K14'=?T+C0 MRE>!/3;P ^'ZWPK7+Q#N&*][ 905-MUEP^NRU0M&"H,-DRVI(JD2;\EMTY4+ M$:O-]>GB!5.%#>&>\2M+PZE>8>#N0JIF4,G_4'(5SZ%<1EALKL-YQD1AD+L0 M@ KS'K1'ZS_IE6!/E N#.:0SIL&7B*^9H.3K%@ RG;0-H(&3,&\+S$K-I2C/ M*!< LP-N N/JGN/9I?">*17(WAB07$O:5J>(9D\NJ>I,3."0^.)N[UCI&-;A M2D)'D2.36)'4'/P\648X7B;:2;@15F#/)G/&]RL04R7#7"P[;S*//JE@ZN7D);^@9+0TRDS+23>0\=(L,R]G6KH].WY)D^YI M8YY14M*\>]'<*F.IU%GX[/0YXZ?4Z3AW123CIM0I.7=Q:\]-I=0).6>5,F.F MU'GYW'IS1D^I$W+^$X2,G))FX^,G0!D=)4W IT_J]I142YIWSSQ>S7@I:=;- M>S2>D5+27/NEC0T9.27-M2]O5LDH*FG^/=U\M*>D5M+\^VRG6,9'6?-N[KZ^ MC)8?D'EOW!-68);VV>P(WIXQ'V:7[/O_ %!+ P04 " #%@*52!UY,)&H5 M "] MNY74#0:;1X!DYA1#,K.PD[*^_W;(--IAG'I , MJ:T=;+U:K>Y6OR2?_^MA9!-RQX3DKO,NIVO%'&&.Z5KXU"X?[^7K,&W)&N'?@PCM1,=U0@^7S<<4LPB@7D@OJ,J+\&,8J&GB]6 MX+^>7FF4JHVBH>FGE7JI7OK?8K%1+"8Z^"V< $G\-4A%*VJZ5M4KB8K7U/Q. M;QEI7R0JUD_[QNF@4NR?&F:Y8I9KQ3XKP_\I Q!,EARHY7ICP6^'/CDRCQ6( M,%_'8;;-QN0C=ZAC:*VX+1K%8*@ &?1B Y1+UK6F#9.5J(2R,J_J>_Y#J&5X, MF: > SC-<$%P-L6R48_;!#+OCSTF)^T&5/;5 '$)-BGFBWJ^I"<:W5+J9;;! M@HPFTO=$>A*2F=JM>U? $FB@UV8:"'\19).BK'&$G]D@JRHW%T#$S8SJ#@4< M9C=013B'TW03]F .LUM@2=88P2B;-"Q?%'#*!:C!!#+2K(9NX/AB4;NP,*/9 M \BW[REQ?RTNI]=?UJUX OJ MR($K1DK(8T\@U8V\44UTDH9JO??\CEID: MU('B0EQ^7HA'PEVC\PDV#@=V69\)' ?Q__*.(?(,:A(^R2 M\483-F4+-^:/-KV-IOC@W[ !3!ZKZY5ZI58O3:8T^9%[/Z"V9.>%U#BKQBXG MQ[YT #'C%@PNJ-UV+/;PF8TW@V%:F@6(>I= "L(EV("A&& R@A4YJB$5V<.0 M1'%M \7@NYSD(\]&'E#OA@(A4FL\6> ':<7%5)C"Q95:FWK+MKS0P/8DSXJ$"^#S7'S.PC*FZYD^^[ON^.&D7//XO>^*ZG M'K%O$-*(GD;QY[,!C)8?T!&WQXT>'S%).NR>W+@CZH1EDO_-&CJVS+W_Y2>] M6CP[+WBI(56/U.:W3L.$7IDX0PF;'S)44!LZM.R[ N!5(( FRRU2U$XKGD]^ M4IQ=//.HA0;"!,:M)J$ +4/ARBG=AY Y*/GMJ#%.)7ZC>I]L#DINAK7NJ. 4 MAB11Q?4QDH ?$;(20?@RB14]$RNO&0W5M6<4P=EW;2M)DK5UYKCMA+YUVKW+ M"]+M-7N7W;7GM1G![F)>W7]WT-J>#_9W9=2!D *^([Y(N,Y6[ M52\15Q"];#JAJY/JJ#=*R]^OE3?/Z\ENOW>J>D':GI6V_ MHSZ%FGJJ59X3RT>7#Q1$(N(SE!\Q'@F5I.LQ$_T8%N$.:?N2M(84_7['!Z7B M45RYO8^AODOX(W^/3_LV(^$"OLN!YFHRVY8>-56<-7J.UE$]IV;=H('OQLMO MNK9-/;E]Y6OR+7*GR.M=+L3:I->P?JFDEMO*LG?N\X%M[OGY >JYHQ.[ W:]F=7XU/W*;0;7YH>?6A'[GY3,=LVZU2NPC(95;U:7;90A4@4 MOAZ!^-RZBQ)L:/9=80((^3=8>]+BRAY\ AUMGZ<.JEI*Q!\OX&B8RX](&"UW M-.)2I5&A["0A4RY"TKZ)O9?#4_NF2RY'GNV.F7CC').6TJ3C:L>9PC6>?APA M,U3T<5N)^U0HRXZ$/DJ[>BK0-@_@/HH%=P_V[#X,6@I8/S )([=\/M6J5JWM M6J3L2G>JS^M.3I->K!HUTC4Y)HB0ED(?N1#\;LX6.5GL M[]2+ZT!F; 99-^"@F1C%XIQ"AZ02KWV&M9Y#4 M8:3$N=7TAQ"WX>25Z[KVS M(;P U 5GM^XFB#,6@J$4LRMQ#58B5_EXF\#2:J[R 2>=2<8Z.1L;2]G=^%A> ME6ZR(T&B9WA_(ZJ[=J5/[?_CWL9.CO=U0\\./;P-H?_<>F2T .A!OA; \=RC M-KE\8&: !RS(U0#T+B:/7Y2/=Y>']*K8^+E) ]B1(#]F:=L%Y4I^/Y])^(HC ML=,(RB\_U0S]]$R2'K.9-X0VD1VJ#M+8 ?K'25,PJO"S)"*KI_*/<8O'5IL+ MN:-:I78\'\U:.&PE.>P7UZ3V-#*1:0C^\2R4>! M[5.'N8&TQT12G\O!6+6,&KA]()[0>1/E]XAIL#J ?@2ASC@N&[@V#([M,%3% MT14HR9%DC'QB#A.@GK0=:!LH9[$D3X%]3+])8LI:0GI=,$@9.1;FW3'(Y ]3TXZ M\\;PCN!8N 6F@G'_$=P'BD7G(I", M(@S.\[!>IGG=2+!Q*@MWPL3EHA;6//#Q@8]7\G$J!^-:,-R-T?VO#DR@.BFN M!H,-S=,#/P,B\V8"DROW9[ULY8VC_O%ZW!W6/?#W@;]7\G=]"7^WI0R8.'#Y MRW%YB>7+>#O0.EP>U5W)Y6L[QQ+'=.-3N^L[Q];*E-[Z*.O4'@F=$$PP*X6^ MR;$D)20CIP2@K+$[YT*]KM7U66$W%Y# "@DZGRO7-ZJP*&=QCFV6N@>SSVL_ M*NSQK.31PYM3PN-7YI"8-I5R7?'QMO @J IRA)O(D5R6I?AVL=")SM8H8F"Q M^ 39 (H$O)D*D'62?5\053LY<+)0,3!2:3J1 ![K1E\QVX89)K#M ?Z[OFM^ M/R'_4]2P.O&H0#0'C'AX[]S1D"=?GF)7I]ZQ M9AA'!'F8-\*?ZQV"UV8CC]LM46V/5^@R&]LAEJ+P:[99/'LCR*Q5G)[BLNS7 MRGS26@S6)P55*P3JA0W:M[WP[<$29CL!%LOD7#X77!X"7S(;##K@2\=5YET@ MF:H%P$0A;(2(*Y,OO%@-%T>-98]Q\'L.0R./.S!=*!'LCDMH-YCI7OPCW/KV%;)/8^[ 6]V MGUP/9UN-.9PY>@>2*/($@ M?Q)7@+=<$)58H*UF_QCKFVET%4VO[-'.<>6 PCLFE?!*FA/2"X2#@OG:Y2"" M>XG;QJ-+T8]0!&/"IU$\:\7Z!3SI9\>@\\D )#@%88XYT@*V$@K;!W4FX.24D/ 5;+%VX=V#TE M\4E11@(/K^#12!/>>5&V%)\SWU2KVOZG.;X MUH@ ;2#N3.YH5IH9C95SA;66NIL[SGE$E\XDRRUVF$.M";N>J'5)XE A%W9T M*D +8;A64[QC73D$;4[I''T&I@&H,BI9KC^AM0&WF151VH1 0%?P7,D43T]T MA5J&&1&",V\4G.!:TY$BK1/45ERT9>Y!82$RZ/\)72(4V)G-:9_;86^J?^H3 M&0V)O=_S*?Q\BVL&BY "DJ<-KQ-0?M<=+]\@]OWT*A>TDJE MM6.CBS6")4[:9SYPM.A@WHM"H61%!;?VK:*.&^/U^6..JP\\1E.]8![L:(%0 MOO(++D"*N$*B]&DQ@8(W.D8DY"\_5>IGY-*.Y$RR>EC4]#SMW."Y<7UJ72-_R=D ]8 MAWR@WT%^P^802N"$;,<5&,8)XFJ-87\ #05HGPR$.TK5Q6U&O51ZC!L:X1(% MNC3'J@BJG0_36CKX-D?&-B%[0OP -IDEBIXC5/'E510MX:<#>8. MUP' :J_%R]Q@M*QN$)N"CY:A)=10/H\%)[_!"OWJ@AJ1#=-O4'T*&,QF@L%M M ,G"?Y8VLX9#,[GKSVW5&[%-]2URXU>I39>6_.DJ?3;%3LO6%E7 V&]>I>?FAG6U(FRE?B=\LT!7S!SZ(!1<#N>^NX4 MPW>9!]ME'_K"C]P0!-%6X(6P70-/"617'.9D!M0I?+.S#IN@/%/R_4?Q< M#RG@SU1 4CL;3"]59P;4CGL70ZK7(T@Y;#74_"O@D=\0E,Q?7<'_AI])G!#/ M-M'BB(0HS#3DTB6@ VJ;=\R&&A^X*\/K$1) F[!)*1A!PU:1:#,+NQ?,G(!\ MBFC\=V"/%?P:^8@5C&*Q@N_A5746O4-F6PEA# !JPLP+I&( & /WO*)Y0!& M0[/5O&@WER ZZ-O43LM_[Q' M$A5YE2D+WD%#/JE'BM!&5>Y\6#LT,?U[QIR9Y5;W2]797C9 IV,!G+L(>X@N=0*$3<,B]51!;$Y82A$TTDH2$ MGU749J0$@ L#A[U@'QB24;_5)/#>:NZH@=12T$C?%^C;0IW 2KT7^/DK,?&0 M6.%G'6=B)\K *A?+4>3DAMT&X71)-_]YD;[P" _QBQJ.=:VH)[_<&#M09-+Q M))?-- M(VJ33)?XQ4TL2RN)ESV<=_K5ARERHOM,M-/:SVY,30BM-W< MH+>;*8>70*QWV\G61!A1NW9J+*,+/&/41/+P-J M):URD $S7^!@TA372>/=W:!>M&<%^-=*U9?]H;)G=QEN0%-KX&R\@M< MROF28@#CAFO<]KL^AO3PT,=;(:H7S=6E)/%]5?90K^M_U/#[N3-QCV5:ZO5, MZ%TE"_3'JW,.TKZX2<"(KG5I^"N1/Z]:*JRX$^Z5<.N!DIZ5DO*@WNZ;6"-Z ML?P*B'9O-/.6>\<$N49G>AO5VM"M2RZH3\/[YX_0DVZAWQK]>"I]"*OB#D#P M<_#$BCZS=JQEL-S"8/.N@LM[@OB4MUFKGO[\M'FY.\E"Z0M2F$NOW"['=X,/ M,3Y78O1KR!C>;9+R-K="AM=0[(Q&N^U/G6;OV\W2CU//9,*M2;J)F>U&DB>_ M+!J> E$QA4E>T%H)"!G'1RR,G9HT4#$+3%0)O\09A2HPL04*0*''F'"?#:D] MB-,=PPA26$&E(V*Z2-@?#?PA!HP?F^CP2ES;6:K'T_FTRI6WK*%L(%H_ 'UV_CUMT1VZ8#LW/L/X\8NQ?>> MI#GLS7(49"$D_Z;C,$Q_[KC"'[[D)G#8;0_Z]PNB]MG-QF<+Z.[>;-^]]DT2 M-\W\X"EJ!X&]1U+E(+!?+VH/ OO%Y,%;EL?3,]SI@YSJM$[\F3(\'RZ9_1K2 M0O;E7IZ*CR5"Z[?/^FT3@:A;9V>6*X;L((1 M&D>?_OZWCWB-_V34P)^A&5H,?@F]\$>>_:C5M#^J!;@)/CI)/OMXDMS]7_D\ MN?U*ZJ[SR/R0^>2Q4B@62H5*D>3S>$/7-8;P\V\?/1*$0XO]6F;? MN?#-_B"\M*G?-YU\UPU#U[XH>NF5T/7XG_P;IF,P)[PH_G39IN!:8?[$+K02/$'_B "XI)1X:(N%Z< &N.DS< M]4CA^_ F$M]X]*GQ8V!VS9#4:@7MXXGW*3.95XU]@:'&TXN'\*;1?S3M/@E\ M_9>COOU7Q7!.C;]*45C$_VB%_WC](\+9^LO1$:%6B#_BN3V91CBX*-5.O1^7 M S&>\RK\#H\<)\)J.!I3I6/:+""W[(FT7)LZD]0Y^O2STPV\RU7P(2M#NFNY M_L4[3I9B]J5:PI)X?%= WS=RY,M=BS1O;AK7S:M.@[0:WQI7[<8*!>L9$FJK M(^%K*+9"L0:5$U(=KNSV-/['M,D-_>LOUZ*KD(!-#OTC7A_3 0;379\B#EU$ M,"[?,N';1Y_^8]H%6\SQ_P&L#)A//1:%IAX4=-?^>(+/F=0I.\;&:J6:+Y^6 M\M72>6GG5O*+;\PJRGDOS8" #L]E_MMQ?09/9RCAU6!\YWOKM@F6S/U=\[9# M.K\V6E?WC>^=9KT-"OK^KM5IDR_-5KN3_^?WJU:GT8*_;J]NZ\VK;_!Y^_NW M3CM'[EMW_VI>-]KD[AZ^WFG>W<*GW^^O06H>$1T9EF!1W73Z:=_>]0PDK^3:8BOY(%1%O4"=I'\S\#3[^8Y#'^,TPS0D[X[2@G?]T^30P0Y;'5R,3GT!1',T1,AS[RR*V MT#H?E[.%A<9B(8AY/J;3Z'7/FW=99H!%;>P,79[1J?^8$,E_O(F($\BRN*K. MP ]_X6>J/_1]%Z H'T^%1J&[Q6G%2#GF%UB.J3S6S-_2W]^5RK7+A\9:=VUM?\F MM^WZMSJY!XH R 3DJH?^^QFY@:$. @*/^>HSBM>^@%9WG_*1=TEPE,GPKAPP MX4P/;C'P'=H_2:E8*I%)X81_?/P',09^ OPL!83QGRBZ%]5"N?R3@L;-0\!H M$2E@G*#*OL'BQB>U?Z"XF=4R!HGEVMG9F:95]@H2F\XC"T*S3T5DFS/]VH\ M>3P /IU?)G6+41\0"'&O[MI=TQ'7 1_'89 Z!KEI_ ;(P:.Y<'O'!_JE&/E; MZZJ=O_;-1P9X&=FN'UR23@O\N=M.OD3:860,"3P7O@2('+JDZ9BA">!';DPC M_[\P" 5\"O@4\"G@4\"W9N#;#W3KW/\[7T2'J?UKL_'M.J_%&'/ONWV?@9,' M+E;'?:*^ 4"FN[;-0/,;Y'Y T9*Y-H-F$(*9IFDBB-V^NB77S<;7N]S/[[2SXN4-'9)*#@5#>TFE'GTBJ%PT[5)\ MM1/Y#KK3]R[(%NED"M!R8//H!7)\>]6^OOKG!>G<=_[] 02:>#[339%H=9 @ M_2$!']RCSI 8[)%9KH;$LDM$;1L*?CB@(0F!\"PD> .\C!@87/;Y MHM"IHS,_!\O @&GY#-.[&,0V'?@ J J71#H7EY:;K VX'GD&&&@BS0MO@V_X M04C^C"BOOA8A EB*^H"4-4&LPFH*[)82S FV:J>@Z4\%6_>A]G2\&J%\#K,K M%^/I(:@5+^\B8 ^C-@B-$YI.A!+A$O8#-&/(R!-8H)RS8(<3J@],D"B#V,!P MTP/]^<"&!$;/@A#& ")J.KH5H;G*1= 2V7>:5 O8<3K^R0P'7"0P1X_BX<(8 M+$8-D+NHCQ)GF"@[.2YN:5X$A#V(!Q00'9,I^##\;@_^@48;FC" M%&\*UX4<+KK 1!X_0V ^EGKCKD!B4O_."/49 ;J 4V.,R-!+JB=ZOFOS*Q,$ MPP=9KON Q.)A-N 0WF:,BBS&:$J[;A3RO\*X\")9I/P-7E)($?*R"3$2H(?N M#F!Q$PV7/1(NR2EI@F0Y N8P+-@I,2(@*4B NP(* (8K?!S \"X<8Q(N/7;QIVH6SVBIH/;?&%E_*C5:A-36>FH89X6XC/YF31_LLWX4E\Y"G6(%T0:TG.@PN)WSN=4OX MJO>6; V.RN?GI^6SVNF,2H#G:O2QR+G3:M0[S=OFYQRO$#OIM'X#\RC.EH]9 M$2KLHN+4*K2PK3CU,VILAE1L,,"P3#"Z'INRHE3G&6O6=0UNJHG*'\,&>S,( M8W_K&.RR#VBWQ38; <,6M# Z4-Q2"D+F"5_)GRR)?=%<.V[\^SZO?<#1X3A\ MUD_?"X^?L.(*Z%5R*[$?F>B#F\NR!C*G\[BI;43<"YEI F.1<6&-H2$!(JNRDQ52JD"\0DL5B%\8 M)P$9,0B#\4$.C YHVO$R6 =8QT,ZQ\W;ZP^$9HIADZB@/EX(Z[]0"!M.%\(: MHA VY(6P MV2^.4[B4.ZN#*(;1KYR2BWL@B41: L M F41[)D'??3I'OPI4#\IKF.2,LF_DZ.8ADE[9S(>+#KD* EQHCBQ M(_X^:<&7'!U?9>IQTA6&9C +$&9G$&.%8]ARXK3I<-/*!"YD91=QWL1,YY@ M\!3^^26F8+BA&@M]NU7/D2]7OW$V_\_5;Z58ZI.E=R1Y(-X41(,'>9CV >$1\@R<1\QS2[$5<@S$?+ >.E3D#3.Z/?VZ : Y$,.4%,TQ8?+'09L5>"'U6N LKEQME[2AK1UD[ MRMK9K+4C-D(EQ1"NTW=Y2#JM7J]?M1JCPA./&6#J@.'#M>W0Y:: $5GAA <^ MT^$D ^J#?N%]+;[])A*@:('<8A*46F%2G3@>"D&_E%?VB JNV#>-C;&T[B0= M(?\#2,@K?ZQ>',U>J^_ZND+'?6L6^(* ?^'_F1+Q;'X\V:V7(S>-S@D:(2?U M]A>MI1+D*D&N$N22)<@7;"-5T2K%4FU[/3/F*J(EM>4T5,80.=I:+" (>T:E M>FPLPYOZ6J#=UB4"FZ0#G!.=9 1& ZGR%0:(4XW/",1XLU) MX-_SW9Z)"ISU,+1A,'@XUB+P4EQ_Q@9M'"$Y;MV7KK&@?+Q75L80&,]L:X5Q MOHPL#'B_SN#;AHG^L344VR12>B0+)B7+N$=N!HFQ() YY5*6 MTE/6$!&)_\SC9S%@U7ZZ\LI7XY6?GN5(J]&9XXKOR>Z)TEMV3^RAQ:.B\&_T M'??:YI$R#K]@6*)<*96KE=("&WB>EX2E>+^&*,8"9E6+A\T1J5]IE\T.N(\Y MPSU0W\(6\Q/K+7//28FT?[]K74]NQPP&O'8>3"7+!(^9^L.1*4&QIH$7)XYV MYKK=_\2E#DDAO8A.4"*VAV-2&G?9YD5U(]IC(@"1!A:F*@4!TD9F%; Z'X", M62)MG$WY'O-&WA_XZVP,A5@XVG P]%W3@)M\$$9@LJJ04VBET$JAU;H]]#EF M^[IBY:^(CB>)9(2'_!QX2,$@#GC/B56O+2Z=6SCZ_$KD3.*_X^XS-J3 C69! M['X+3QG>'KI =IQ)O!]^X$* MMQ5N[QYN3S;5T;3BK#81FX+T!4!J;"LQU- M]E$2GB+OX22&H( YB)?R&G<>??:FY&H<>U31U:X4 M76T#7)8NH6J.MI5.10B3+MGC>4/LI&TZZRWL>IUW-TF@\;BBY8H],FD=-&:. M64B#D.^2PK," 9B2)AV ,*,H)(\T9O?F,L?@2=*T3UH2U1151=F-W#/=/YO^ M,.W()J.H*':55 NRFPZX$'X.[<5J->K/=(5I!\KW!8V;9>;%V M6BN7R].],O<0WE31DG*N]J9L:7P5%RNU6K**976N7EG3Q*.6:5U3UAE#WP6\ MG[@'5-=R72,O'(XN]7W<]!G7^PC=S1^"-3]]N"407@Y)W9SC9OUC$'6GYU.M M_'1)'IG/MWK&^ M:5KM[(;T <$>&+AB_NK>4!%OX#G")'*+/BM*XFC6;WO-SU9X231.]RXO)<,P M,&8K/=^US%[2))L& 1T&>U=,E=5*V^VCKE7*YY7*:5Q!P'O>DG_&9>9?T@[C MR8'1Z^X@?)B'NH)!J=QF_C)]64 M*F")V?%1-1AXZ#OP*B/;CC39KA6'.]"ZA*^E7XH\81EZ=&C'=J)-_H^:Y!OM MDN/V@#K] 34_D+I;(-]"HY CG% SLQB6J3,,:-"^SYAX6F)LQ[L'OO(8C4_J M T!U8=R]+V:FP-\^LNDQ?8'E_]80+?5D5/,',-Z.9VHX2UIP+ZW8^?[>^O+Y MRN*04R/NK<4Q28&]L#C6/JGG@>#%URN+8\KBV&T#X6=J>Y?7_# Y++1>C:60 MF -Q:SP$T_BD+XZ]+'X9><**P/>G6J&6Q,5D>?QM]QTQZ M!]NB[;J;3&CR!*A,4X!X0Q6?_JC( GN[XPN&6)$H-I1C (_Y@>LXS$J)LV*3 M8!LE?LHDD%-E*9- F03*)-A< NNLJ)TOEL"2W%KXRJV%J[58"U_%WBZ19LH< M3?/()NV%4C'%]#'KH%PKU!:T#AH_DH04)4#=? @RS?>%Z7@@;Q"Z^D->Y%WP M#?!RD6[!+0=]-MH<-_/I.?Z@KU=7]R2A5SJ!9R1CU#4 3)'WFC:R7'(9:\5G MH@$!S!7JGC29'"WO#='N,',V*])/,?35V9',KD M4":',CF4R;&#ZVNW[8I;%N+AX:[-3KZYP4K-"GRTA74TZ/6_+U3YXBO9\<^&/;('+/(MB.7C=[1XK9=5C9?^TS*I07.GJ MUZNU9=V2U;07C;7=2AZ66TTE?NIEK>9IB?I?R=/&G;FS41YY)4_?F)^FO++] MUD3**U->F?+*-A0(KE1*U=/RN;8/@> Z.C7)B=47J\%,?&:.<'>)_1F9("]I MSW)@] ,3B!$P/?+AM=@9)B0W/+^,:57LFPV.7 C?,LA[K:"1;A(]'0L29SXA ME#M[UTPO)(\ =R[.!X]"KHC@8]5L)A:T\4JW'($'X]X-"[B"@<"WR?7ZTG9><&R/:M0.W3F7:^)#.^,6-:+ CASM7L@]AD3Y_?V!#E/QG^Q D# M7+7$1:H7Z][BL9Z]-)LD9BM;$+-_]K_,_6I>/)UL P:_ZO:D3E'8R[4CYVD* M+4;! A8'_21' %>*H_:WGNNB13S5SQ?-ZJ0'1-RO,4@Z271:S>O&;2?MTA'7 M4N Y?J/^%=C;PJ$_ORN5:Y=).XODM7''0G+<^/=]7ON #Q@_HF=GNA0JY-K, MZMMFB$HAED*LO5HS]]]]$TF#B3-'48T1,<;U85>=B4=])G+,WS"S,GF"J_3J&, M0AF%,@IE#A=EQ$%D)#E.;!Q:4DQ)#HX9=0:N7[4:&=>.&> L^J;.\6GHXB%= MU ?<>3T[3#\J/SA_/QALH-> ;44P20%T J@%4#O0P V=?\6TU12"C9T; M^LJ!3YPGU_ZUV?AVO3DO5/F4P U)?K*])CS.C"Q'*[[& JK)%DO2BL45BCL&;/L8;7JL3X4IK&%P22;/T* MKU;!))P'[AA2BL#$GN!:C^JABT='ZLS#7XX;7[^T/I 0MW>'XAAI4 8[Y/+L MZB'/]Z/S>TZ2-J8*6*52#@I8%; J8'TEL(X=A:&5S\^+Y>WM2UX <^^B$#N2@6B5>P"Z31.2FE?]QW"N3:+\#7(R=T(]]T0S,0KQNX\"Y^ MS @\+SD\G7_2983J.G;V1)LD',#B[0_XK4=-WK_<]8,C7"UI9,031B6+8*4$ M!3!3\0S;[I 80#JK^9*F5A@":?D:%Z+'>CGY=IY12L7R!6V M4[> ,.ED'JEIT07GLF"W@TF=]/3T5)@F0ZP+"B]OVF[@?U??3&?QP][6-+CL M -:K*JZZ("QD?%UU,OS YH"3C-CM]GBG;VF/MZN*\RWM+M:KQ+/")E02J-I1 MGA3> ISAI[J: 5>Z0D; [21B4+I\-X@R9D/O)\ :BZS MSY52?))4 /9( ((R7Z8 >_OH>.^#C^.!_". M(IU9IUYASV=^5%5JX\SNO;9E7OCC'0.D&Q]8E 'O$ K?Z/,VY1QQ'DQ'--<> MF%T3PS4B3I-T6\'MLN+LC]9O7&#@JZ8N^LOXG)W8P2ZPT23@1[M:T8BSH@OZ MC.T[*^D=LVH"M:1GH#"1@(U=AOS!$)TINGM0,#GZ<:]YOB*3]%%:7<#+#H/X M_.-1O>*,4L6D-#$'CDA @H'[Y' 7A+,N:R[OVDYM%T8V M+51X,!TZ*MG=UJ*%.\OS#V$>R8MGZX&L5AI7!_!6*W"3YB9!)B,VDN6;1B=' MZNTO6HN_MMVJ/T_.I'PD1%;RP[#'=NFE4@USLUD(5C-\K(]O41M0O^ORMD6X MW/!C:H69]C\RK@$@DX2CNDR/(H7Y!+'Q 'WPXI;(>I(-C_2P\C'L H-N;5B,+ _1%C5P.0D[9H6?[)+P+B# M=1>W.03C%1OUC^P2-&'@O2@P^'P[27"Z.(KI28^9**@/XH:+F2/UTN&+T6'W M1YA"&!/9XQX;-N6?V D")$O\HF1L!?(%9=WU<03(1LZ)''D$$H8S)6E%8:-G M@^#9./,B$8T-1IA7-(9-+KYW[]ZM>U/-*T)Q.SN&S47];I,&[E] 1S@Z O\- MHP%HI6#7]BPUT4LT1-M2H;^QYCV>%,R'.Y!>0E7K M_) NKNC =M9-SP)9$"B"^A>C^U[LIC$!=)T1*]= M/;*H+UZ3#B,9>?+"!4YRB\]*$^>I<D*F1N?6\]?..F$^T!$+\<6 C1RU.-(&L^@T)H241SKA:8*_^/9$8I\35/Y$ M^&Z&AUUFF0#AR-RQ]T[+&!^!:6.%+D[83 [CX;'-N.%O,HB8T*;KYST&/XSD M$Y$N GG1P5*AV5+?V<*),YLONFB*Q'&0=''1,*3Z -OGI7=GS(C)C(12^2_J M2;#&GJAOD&^N^X"\YFJ+'ZF\:QI_-/)$J29B,Z5Y?=:'.>-T06Y"C/VF2( * M#[X =C'?CH7U?V)M\!(5]&0XO?)63*\@?2N_0;ODJR.65EA<3JQB>&DBV-68 M?FZ/.J9_,Y/, VDQG"*YTGG[+:U6JQ1(.P(/??XKD^61O93.+1?'+X75CV/J MQVC >J@,]6&.!+3'XO!GQFP>N1>\9O*9O S7=),1S-S2)W#CH%*\PK(1<(7P MC$VWS]G&AV?:,25?'H\_[YAS_D1J!^,=5GB$ [6]!6*6D8U>Q/TQOB,/Y0>A M-@:&J>_"MP &06J&P'0>TA,OR5P/HJYM\@,^@V3&Z6?40\4.SP,'BC-\DH0Q MA]!-9$X??;E%"-&E%H>'8 !C2I]!#?9G!.S'9W!,!N$#9]4HD,],IQ&LCR#B M!3VI3*'\P_"Q+3P'(S-X$-.+G-B0"+EK"XLERNAOFR((]WH@?C:ZRL)?C7[,$> N +Q&T >/'2Y/R+5V$NN8AE"Y/7$E3, M)4LVOCZJ31I]M%CX#)OA489A'GCL[ M%[#=.-XL'2?%*%,+6W%_H=PM(;$ 24T4HTP7AX& MA@\0#%CL;@'$NSX"00%-@ZQZ!;?4,IY7L!/G)KR@5^5@.?=^Q!P!H:08$L%+ MX%3.1[XXER+,,1'CQ0*J4;5(;MYWISQ8*6:\(^NNBP6,:"*"<,<1F5>>9;CJ MH+3%3!']CQV$^MV_FM=YK09F(*AV&RQQN&UV*B.=N12S34Q+X6N( MN1LLT'VS*S2/%*/<$:'NF1;W']+ 4KM1!^5O6<^I[I=WY9$Y%T=["FTA733UR-;9#+CSWBHEG _Y441 MEH(LZTTM;M3+ZOKD9.%Y[(1#?+:5HN\79SB[V]OJI6>AC4B+[65[K4PE^][: MG:M.XZ9QVVG_<7??:%UUFG>W[3_J=S?WK<:OC=MV\U^-/[[=M=L+[8F+3^T# M+?F]==N\_4KN[YJW'=+Y%1Y\W_C>:=;;.=*\K8^O3;&9;.F]P_'V1,&'=)/K MJW<2VZ9A6.R(D,]?ZW??[EJ_',73.1J))W^Y:%*"W$DNM#@WBX7S2N9B!_D_ M?NGS2$C$8&JU"8E^A7QE.Z?@W^,"AQ;;H,1VJP= MT4LJFYUAA-C6D2'^B5@+J1X>B"&6"M4*5X5;9\]FULG;N+%"=#R>NU^=2PTO MLL X1P#N7Q"KT@]O1ZI]HE#DT,C >I L>9[1-?&3A+CQK=UK6?RO;ND@ENB& M]U]/&T)R0+68YV954*5:."\M:W^^+!7+B,6J%]%S?4.V06*M4%D]@1?&W.I: M(7<&J6$@L&: UJ6C[9*]5M F)7N[=NA:67'#*Q3*6DXBP9?+^MSX2E!*Y_"4 M3J50J1Z.TKEF.K.[S%=Z1Z;%H/3.9DB=Q!@IPY%H%_O1M2_?"E^J>]>,F 1NB^1*EA=HOYB87E? M.^FWYC=O@/!+ZI;UTWJ$L$C+F? JB>(_1.Y4QWRU5W-H:Q!RB#R3QE(Z1.*O M SK>1MKM9?,/!3P4?^;QYW3,A58\DI%'&X$+17X%&%M)TVW:OY:&]'4:#'*B M!PC[,S*!U*)7-F[GA&D\,%%A&:3]:O8\;RT-8Z2K$C@L '@O$>6%=[V$\^SC MJ]949;\==F@Y33O-G9^?2\26PUH0TNDCI?V5L!^"]A?.\:%K_U(I5RE6)6++ M82T(Z?3186G_O<\W2T/ZWUV?]]71J6>&U%(1("GUBPIW[CGYE\JM6Q9ZO"@4!2M@/AOS*[T6_MWB6*U47CWJJ5;'GJ^*P($#E@3=%^HZ+ MATC1(&"A2O'*J5Q43'//R:^<7A[I!Z>W>BH16]2J4!!P,-16PJZ2O5N'@/)9 M[EPK2\06M2H4!,CG]*ID[QM)?Z7KD1V)TW@,UC-U,U2A'BEUC(IK[CGYE>_[ MZ;BL57)GU<5;IZA%L5H&S.G,KI3_WFN?PY)SZ=GTG$E<-: M%$KY2^_OJB3O2I*\0>CJ#P/7,I@?_(/O^@V'*M@C)?2JR.9JR2_3OB[E\?+Z M-OC_644BMAS6@I!.'RGMKX3]$+2_A4]BK5.["T1Y&Q7W\ 3ZYAWIWEWVR97M]>D?G=SWVK\VKAM-__5(-_NVNU] M)<-Q]@SK'&$_=.:%)!A0G_$V>![SD[]L-W+"8 4'7$]08L=/LUZ]5"PV^U5" MV@($7@!6]_Y4ZCA0?EXHGVWY]#3Y3&:8P%I/7#E[[1&":_59ZC![L.NV0?CT M#*BSH[4S8:[34JX6RJ>[= #4!OKM=P8^8^0&/AP$I 'C,\C-\X==KWGMJ,,. M)%=1:UD-\@9:MG4.[79Q6UY^[,(2V7L4+VT1Q;7S0O5T@3,H%,PO=""M@O.] M@_-7+0GY3JO=$L>4DMM5;LX_S58IN;U15F8I>-Q_;VW7>^\YA/0Y@Z83\\Y@0LN-AL MN$@)O RT5HI]>[07%I"BOY+]PZ.]TO%*S@^!]DK'*]D_5-H?F(Y?S'&5/^D+ M*JLB-^E;+&"\_!VWDQGLD5FN9\,P5<1FVTI&-=8[//(O9N+L=9S^5,N5SA8_ M8$$MB3U?$@H E+0?#OD5 'PJE7+G9S6)>**6A ( V5S?'=U[*;\__)4YS,?C M9L$=IH9M.F808G+W<<'2Z,/8DKGM1;+M9G"+]510L+%%%HW7Q+V%37MM;6FU M7*TV9Z?LVO?\O[".LKI-K:5-\41!CI3Z3$&.]"Q2D+,0W\JU7+5RKB!')IXH MR)&0!YO-@F\X%% J%B0/!8@CB=RIXN[-IL;5$I$Y.+FBCB4*:K:><]D('_?: MKCO3U37G9F'-I7/ MF^WP$M.][MP MP'QB.KIKLQQQF-KX+B,:2Y$3.23%+QU_E+7T,M,JIW,ZHJMMDX>W8!1^*/Q0 M_%'XLL%RM6)6(9PI!%(+(YG#OZ,9[R9EQRT)BN<&&,]VJX$/F^+BJ4MQ] M'JHJQ56ET2NY2G'QVGJU9W(ODR,*L&16=@JP=I^'"K!6E;@OYLZUQ8,)"K 4 M8!T<8.WU_G[Y6_U]=WP&-/^+&3SV0%R'P 0>6$B[%B,!TR/?#$VUWU^F);/M MF*BR\7:?A\K&6Y&-IU75QDFI.+*X@:?0ZA TG4*KW>>A0JM5A= UA592<42A ME5R:3IX"",.-T 4O%0Z&&777]GPV8$Y@/C*Y2B$.CQG29266Q_\QIAVB'?=> M(O:]SH1[%0OWW(2KY,YJ16F22G,UXR$M-*F22@JKMJ[L%%8IK%)8]>GX3,L5 MR_)4["FL4EBU;?(O&'&P3<.PV,9K( Z/'\FN"^(QGP0#F&V.=&E@ZOST0\.T MHI 9TE0_'!Y_I,M%C!L&,T%?V7:OM>VVD4I:&POWV[8#2I>ER24IRTZV7))" MJJVK.H54"JD44GTZ!OVT>/-=A50*J0X.J535P_:8\3M_%#/R])'YM,^([MJV MZXA81$#<* Q"ZB -7QV84(&\[9M[FTXZ*7-O%WFH;+[5,/:TFJN5BKG3XN(A M"I5\VM\%IX!K^SQ0P+7//%3 M1K&EBNYFE;+E2ORM(U0P/7"@CLP=TL0.:'Q M<^Q8?\CBA/:=;;.=*\ MK1?&A%/H#-'I1*C77XZ*1T1GEH6@!MHX_3O6SOSO6.L+@J9:/M;/,""+>@&[ M2'ZY)!/BL$"EU]K-M5KMI[DVU:*"\C)V[)CLM)CN.KIIF?S 6>+VR->KJWL2 MNN36=?+\]R^F0^$6:I$6"R(K##+R-&T7;(.SF^D7+@EG?WZGG15?54NY)ROL M;61?98YU;)%-BU@M4\4BAP:&2;/Z8S(\XQ2B9\D MQ(U&H;N>5;Z8N[6T@;XQ6T@.D%^[VUZI%LZWN*%?5M=\ S'ERO:HOC ,5]>* MPC/H#P.!20,#SHZV&IS%$FHW7CJV4'M-4>+X@%JZ&DAO!#8L]N+)B]IG\*[Z7MPKM6*VBE MY7=J'S3^EXHE3>'\ :FM5ZT*A322:;I*H5)5FFY93;?%/DE*TVU,TQV*0+_> M4UG[;K78>=G;^A^>_L->$=_FMJ7<" M#];#OC+^$P6A#0,++B3:V'98XKYM:A^66I>._,*)5BQ0*^!0R:_4O1+V@R&_ M<'T5"]0*.%3R'Y:ZWWBZ>,-[4[1RX5QNEK2QJ5^^2P.&I46VQYQ [#9E/_!W M1HZU[?7&W&*IJS0,DCAS\%Q)EP(1:5+/;V'37B<1?GY7+6G:YAFGSI^6;S$I MR-DZ"Q3D[#"+QI/6"G+F\*VLY4Z+%84X,O%$(8Y\+)!JQ^OA=>1-^TLM76"^ M_MVNA\<-Z8*4ZC3I-188;BJIKDZ3WG3U^LIW]*F^R#*=)JV@2D'5/O!0)JA: ML!9>0=5+4%6JYG9[YZ]J#XC=5>U#5'E3U M#Y.DJXYJ#RH;NU1[4.E6RPYHJSU>$'(G2Q1[=G/![#7]I6F:I]J#+LU/U1[T MP-26:@^Z#YI.M0=]C:93[4$/0=,=BD!O?[_77/VT[\U+>/765^8PGUKD9VI[ ME^3*L$W'#.#[H?G()*H=/JP]C]NFMNK\)FWG-]4R=(%,ME;+U6J+>X2J\]NV MDM8*.!1P[/%"D DX5,O01:IU:[EJY5PBKBG@4,"Q">!0+4-5R]#]I;F$)>>' MI-:E([]J&;IU%BCR*W5_,-16PB[!#B'% K4"#I7\AZ7N5@U+47? MW$04)I4*F[CUM*"=SZH6FJ=!<>QSA".F8771%15+#(U"=^:*G$/EA67!8F$( M5(H)>B%8\A%O3>:UN.P93'=]7E,A7OB9Z@]]WXT<(Y^=QE:FQ(L[\/9/L_4. M,GVSW'S+?+)TJE.["U_(DK(TS<4YO)C)-_AJ3*KL$\9UU^Q[EF#GY..N(Q]F M1\(!(SW3#T+R9T1]F#=Q>P0[S.3X1W77]J@S)#X,N>_ BPQB.D H)Z_38 ## M"TR,#(Q,#0R.2YX